header_manufacturing
From RUO to GMP

Antibody-Oligonucleotide Conjugate (AOC) Manufacturing for Clinical Readiness

Inquire Now

From Research to GMP

Scalable Manufacturing for Antibody-Oligonucleotide Conjugates (AOCs)

Antibody-Oligonucleotide Conjugates (AOCs) combine the targeting properties of monoclonal antibodies with the  therapeutic effectiveness of oligonucleotides in a single conjugated modality. 

As you prepare for your first clinical milestones, BioSpring provides phase-appropriate manufacturing, process development, and analytical support to rapidly scale your AOC program from research to GMP supply. BioSpring has years of experience with manufacturing and analysis of AOCs. 

Our development approach is designed to support a smooth transition from bench to bedside, with a clear path toward later-stages and commercial supply.

The research to GMP Challenge

Scaling AOC Programs from Research to the Clinic

Moving AOC programs into early clinical development presents unique challenges. Key considerations at this stage include: 

  • Scaling up manufacturing processes
  • Developing and validating analytical methods to meet regulatory expectations
  • Establishing appropriate GMP documentation such as batch records
  • Addressing increasing regulatory requirements, even in Phase I

With decades of experience, BioSpring is the partner that helps you navigate these challenges with confidence.

What We Deliver

Phase-Appropriate Solutions, Designed for First-In-Human Sucess and Beyond

With three decades of oligonucleotide manufacturing and analytical expertise, BioSpring advances your AOC program through every clinical phase with:

IconsShape_114

mobile-tick-icon
Optimized Process Development

Scalable, reproducible processes from lab-scale to GMP supply, leveraging platform technologies to save development time and reduce costs.

IconsShape_114

mobile-tick-icon
Development & Validation of Analytical Methods

Purity- and stability-indicating analytical methods for oligonucleotide drug substance, conjugated intermediates, and final AOC product.

IconsShape_114

mobile-tick-icon
Bioconjugation and Purification Options

Execution of conjugation and purification steps either in-house or in collaboration with your preferred partner, aligned with your development strategy, clinical phase, and regulatory requirements.

IconsShape_114

mobile-tick-icon
Clinical-Grade GMP Manufacturing

Flexible batch sizes tailored to your needs across all clinical phases, from grams to tens of kilograms.

IconsShape_114

mobile-tick-icon
Regulatory & Documentation Support

Full traceability, GMP-compliant batch records, QC data packages, and scientific writing expertise.

IconsShape_114

mobile-tick-icon
Dedicated Development Teams

Cross-departmental coordination and project chemists ensuring timely execution and seamless scale-up.

Built to Scale

Purpose-Built Facilities to Support Every Clinical Phase

  • GMP-certified facilities (FDA-, ANVISA-inspected, PMDA registered)
  • Manufacturing and process technologies backed by over 20 years of experience
  • Capacity to immediately onboard your program
  • Nine in-house QC laboratories
  • Robust analytical techniques for every stage of your program
Standort Fechenheim_Übersicht_V8_Site I + Site II labelled

Your Research to GMP Pathway

The Journey from Research-Grade to GMP Production

  1. Initial Sequence Review & Manufacturability Assessment - manufacturing of multiple lead candidates and evaluation of the oligonucleotide sequences to provide early insights into their manufacturability, defining a clear course for process setup and scale-up.
  2. Process Adaption - small scale test run to confirm purity and yield expectations. Optionally, the process can be further adapted and optimized on client request.
  3. Analytical Development - establishment of phase-appropriate analytical methods.
  4. Conjugation Strategy & Process Setup
    Definition of a suitable conjugation approach, including linker strategy, in-process controls, and purification concept, executed in-house or with selected partners and aligned with the clinical development stage.
  5. Pre-GMP Engineering / Tox Batch - confirmatory scale-up batch prior to GMP manufacturing, where required, commonly used for regulatory tox studies.
  6. GMP Production (ICH Q7) - compliant batch manufacture with in-process controls, full QC testing, and documentation.

This structured pathway ensures a transition into Phase I and beyond, reducing unnecessary scale-up risks from the very first GMP batch and establishing a solid foundation for later-stage and commercial manufacturing.

Hundreds of oligonucleotide programs successfully supported

Let Us Help Bring Your AOC Program to the Clinic - And Beyond

We have helped hundreds of oligonucleotide programs enter the clinic. Now, let us do the same for Yours!

  • Dedicated to synthetic nucleic acids since 1997 - specialized in siRNA, ASOs, aptamers, guide RNAs, mRNA, and more! 
  • Trusted by leading pharma and biotech companies worldwide
  • End-to-end capabilities - from early development through commercial GMP supply
  • Dedicated technical teams with extensive expertise

What comes next

Let's Build Your Clinical Manufacturing Pathway - Together

Whether you’re entering Phase I or still defining your development roadmap, BioSpring can help you bridge the research to GMP transition with confidence.

Request Free Consultation

Your contact information